Concepedia

John M. Timmerman

JM

Statistics

Publications

72

Citations

20.7K

H-Index

39

Active since

1991

Affiliations

University of California, Los Angeles(Current)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Mayo Clinic in Arizona

Stanford University

John M. Timmerman is an author at University of California, Los Angeles specializing in medicine, immunology, and oncology.

ORCID

Top concepts

Publications per year

1991–2024

72

Publications

72

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.7K citations · Full text

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.2K citations

, , +9

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Javier Muñoz, André Goy et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand et al. · Journal of Clinical Oncology · 2016 · 1K citations · Full text

1–5 of 72